Oslo, August 11, 2025 - Navamedic ASA (OSE: Nava) will be presenting its 2nd
quarter/1st half 2025 results on Thursday, August 14, 2025. The presentation
will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30
CET. A link to the webcast and the presentation will be available through the
Navamedic web site on the following link:
https://navamedic.com/investors/financial-results/
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to
empower people to live healthier and more fulfilling lives. What sets us apart
is our deep-rooted commitment to understanding the needs and requirements of the
countries where we are present. Our local insight and competence enable us to
understand the specific needs of each country where we operate and ultimately to
gain market access. This makes us a preferred partner for international
companies expanding their footprint across the Nordics and Benelux regions,
through either in-licensing or out-licensing. Navamedic has been listed on the
Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo,
Norway. For more information, please visit www.Navamedic.com